A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500024 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Marius Amann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Hermann-Herder-Str. 9, 79104, Freiburg im Breisgau, Germany. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Protozoan Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The rise of drug resistances in malaria necessitates the exploration of novel therapeutic strategies. Targeting epigenetic pathways could open new, promising treatment avenues. In this study, the focus is on the essential Bromodomain protein 1 ( Pf BDP1) of the malaria pathogen Plasmodium falciparum. Utilizing the pan‐selective bromodomain inhibitor MPM6, a potent initial hit is identified and it is subsequently developed into a nanomolar binder. Through a combination of virtual docking, isothermal titration calorimetry, and X‐ray crystallography, the molecular interactions of the new inhibitors with the bromodomain (BRD) of the protein ( Pf BDP1‐BRD) are elucidated. The findings include the first co‐crystallized inhibitors with the structures of Pf BRD1‐BRD as well as the bromodomain of the close homologous protein of Plasmodium vivax ( Pv BDP1‐BRD). The structures provide new insights into their binding mechanisms. Further validation using conditional knockdown of Pf BDP1 in P. falciparum demonstrates parasite sensitivity to the inhibitor, underscoring its potential in a targeted therapeutic approach against malaria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Hermann-Herder-Str. 9, 79104, Freiburg im Breisgau, Germany.
- Institut für Biochemie, Albert-Ludwigs-Universität Freiburg, Alberstrasse 21, 79104, Freiburg im Breisgau, Germany.
- Institut für Organische Chemie und Biochemie, Albert-Ludwigs-Universität Freiburg, Albertstrasse 21, 79104, Freiburg im Breisgau, Germany.
- Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Wasserturmstr. 3-5, 91054, Erlangen, Germany.
ORCID-Profile: Marius Amann, Bernhard Breit, Oliver Einsle, Martin Hügle, Michaela Petter, Stefan Günther
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Amann, M., Warstat, R., Rechten, K. K., Theuer, P., Schustereder, M., Clavey, S., Breit, B., Einsle, O., Hügle, M., Petter, M., & Günther, S. (2025). A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum. ChemMedChem. https://doi.org/10.1002/cmdc.202500024
Vancouver
Amann M, Warstat R, Rechten KK, Theuer P, Schustereder M, Clavey S, et al. A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum. ChemMedChem. 2025. doi:10.1002/cmdc.202500024
BibTeX
@article{Amann2025,
author = {Amann, Marius and Warstat, Robin and Rechten, Kay Kristin and Theuer, Philip and Schustereder, Magdalena and Clavey, Sophie and Breit, Bernhard and Einsle, Oliver and Hügle, Martin and Petter, Michaela and Günther, Stefan},
title = {A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500024}
}
EUVIMED